Prostate Cancer
Conditions
Interventions
experiment group:indomethacin treatment
control group:Abiraterone treatment
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Patients with written informed consent; 2. Males aged 18 or above; 3. Patients with prostate malignant adenoma confirmed by histology or cytology; 4. Patients with mcrpc assessed by researchers according to NCCN, Eau or cau guidelines; 5. Blood cell count at the time of screening: hemoglobin >= 9.0 g / dl, absolute neutrophil count >= 1.5 x 10^9 / L, platelet count >= 100 x 10^9 / L (at the time of screening, subjects should not receive any growth factor treatment within 4 weeks before obtaining laboratory blood samples, or blood transfusion within 7 days before obtaining samples); 6. The screening values of serum alanine aminotransferase and / or aspartate aminotransferase were <= 1.5 x ULN, total bilirubin <= ULN, creatinine <=2.0 x ULN; 7. The patient did not receive any chemotherapy, abirateron, enzalutamide, radium-233, sipuleucel-t and other treatments to improve the survival of the patient.
Exclusion criteria
Exclusion criteria: 1. Patients with non metastatic hormone resistant prostate cancer; 2. Patients in the control group who could not complete the DP chemotherapy cycle due to failure of treatment and serious side effects; 3. Patients in the experimental group who could not complete the DC chemotherapy cycle, continuous treatment with abiraterone or continuous treatment with targeted therapy due to treatment failure and serious side effects; 4. Patients who have contraindications to CT and MRI contrast media and cannot complete follow-up review; 5. Patients who have received systemic therapy other than ADT; 6. Patients who are known to be allergic to any kind of research drug, similar drugs or excipients in research drug preparations; 7. Patients with any of the following conditions within 6 months before enrollment: stroke, myocardial infarction, severe / unstable angina pectoris, coronary artery / peripheral artery bypass grafting, congestive heart failure (New York Heart Association grade III or IV); 8. Patients with active viral hepatitis, known human immunodeficiency virus infection with detectable viral load, or chronic liver disease requiring treatment; 9. Patients with any other serious or unstable disease or medical, social or psychological condition that may endanger the safety of the subjects and / or affect their compliance with the test procedures, or may prevent the subjects from participating in the study or evaluating the results of the study; 10. Patients who cannot swallow oral medicine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS;PFS;PSA response rate; | — |
Countries
China
Contacts
Public ContactZhiqun Shang
The Second Hospital of Tianjin Medical University
Outcome results
None listed